Bausch Health Companies Inc. Current Federal Tax Expense (Benefit)
Bausch Health Companies Inc. (BHC) reported Current Federal Tax Expense (Benefit) of -$25.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-19.
Financial Statements › Expense Statement › Income Tax
us-gaap:CurrentFederalTaxExpenseBenefit · last filed 2026-02-19
- Bausch Health Companies Inc. current federal tax expense (benefit) for the quarter ending 2025-12-31 was $11.00M.
- Bausch Health Companies Inc. current federal tax expense (benefit) for the quarter ending 2025-09-30 was $0.00.
- Bausch Health Companies Inc. current federal tax expense (benefit) for fiscal 2025 was -$25.00M, a 377.78% decline from fiscal 2024.
- Bausch Health Companies Inc. current federal tax expense (benefit) for fiscal 2024 was $9.00M, a 57.14% decline from fiscal 2023.
- Bausch Health Companies Inc. current federal tax expense (benefit) for fiscal 2023 was $21.00M, a 40.00% increase from fiscal 2022.
- Bausch Health Companies Inc. current federal tax expense (benefit) for fiscal 2022 was $15.00M, a 34.78% decline from fiscal 2021.
| Period end | Current Federal Tax Expense (Benefit) 3 month | Current Federal Tax Expense (Benefit) 6 month | Current Federal Tax Expense (Benefit) 9 month | Current Federal Tax Expense (Benefit) 12 month | Current Federal Tax Expense (Benefit) 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $11.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $11.00M derived: sum of 2 quarters · filed 2026-02-19 | -$25.00M 10-K · filed 2026-02-19 | ||
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | -$36.00M 10-Q · filed 2025-10-30 | |||
| 2025-06-30 | -$36.00M 10-Q · filed 2025-07-31 | ||||
| 2024-12-31 | $9.00M 10-K · filed 2026-02-19 | ||||
| 2023-12-31 | $21.00M 10-K · filed 2026-02-19 | ||||
| 2022-12-31 | $15.00M 10-K · filed 2025-02-20 | ||||
| 2021-12-31 | $23.00M 10-K · filed 2024-02-22 | ||||
| 2020-12-31 | $8.00M 10-K · filed 2023-02-23 | ||||
| 2019-12-31 | $12.00M 8-K · filed 2022-05-11 | ||||
| 2018-12-31 | $0.00 8-K · filed 2021-05-04 | ||||
| 2017-12-31 | $20.00M 10-K · filed 2020-02-19 | ||||
| 2016-12-31 | $0.00 10-K · filed 2019-02-20 | ||||
| 2015-12-31 | $0.00 8-K · filed 2018-08-10 | ||||
| 2014-12-31 | $1.00M 10-K · filed 2017-03-01 | $600.00K 10-K · filed 2015-02-25 | |||
| 2013-12-31 | $3.40M 10-K · filed 2016-04-29 | $3.40M 10-K · filed 2014-02-28 | |||
| 2012-12-31 | $7.20M 10-K · filed 2015-02-25 | $7.19M 10-K · filed 2014-02-28 | |||
| 2011-12-31 | $3.55M 10-K · filed 2014-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 |